V. Leshchenko

发表

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia

A. Stuart, S. Parekh, E. Epner, 2015, Science Translational Medicine.

Growth Inhibition and Death Induction in Tumor Cells by Inhibitors of Phospholipase A2 and Lipoxygenase

L. Kublik, V. Shaposhnikova, M. Levitman, 2001, Biology Bulletin of the Russian Academy of Sciences.

Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach

J. Dudley, B. Barlogie, A. Laganà, 2018, JCO precision oncology.

Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma

J. Sparano, B. H. Ye, S. Parekh, 2012, Clinical Cancer Research.

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

V. Seshan, B. Tycko, G. Bhagat, 2011, Blood.

Small Heat Shock Protein hsp27 as a Possible Mediator of Intercellular Adhesion-Induced Drug Resistance in Human Larynx Carcinoma HEp-2 Cells

A. Kruglov, V. Akatov, R. Yakubovskaya, 2003, Bioscience reports.

Cancer Therapy : Preclinical IntegrativeGenomicAnalysis of TemozolomideResistance in Diffuse Large B-Cell Lymphoma

S. Parekh, V. Leshchenko, Zewei Jiang, 2014 .

Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma

S. Parekh, V. Leshchenko, Zewei Jiang, 2013, Clinical Cancer Research.

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2022, Journal of Hematology & Oncology.

Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma

M. Aladjem, M. Kester, A. Stuart, 2022, Oncotarget.

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma

W. Wilson, A. Wiestner, K. Dunleavy, 2015, Oncotarget.

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2022, Journal of Hematology & Oncology.

ADAR1 can drive Multiple Myeloma progression by acting both as an RNA editor of specific transcripts and as a DNA mutator of their cognate genes

R. Pecori, A. Laganà, F. Papavasiliou, 2020, bioRxiv.

J. Dudley, A. Laganà, J. Keats, 2020, Science advances.

Discovery of a first-in-class EZH2 selective degrader

A. Laganà, E. Guccione, R. Parsons, 2019, Nature Chemical Biology.

Combined Vitamins B12b and C Induce the Glutathione Depletion and the Death of Epidermoid Human Larynx Carcinoma Cells HEp-2

V. Teplova, A. Kruglov, V. Akatov, 2000, Bioscience reports.

SOX11 augments BCR signaling to drive MCL-like tumor development.

R. Shaknovich, Adeeb H. Rahman, S. Parekh, 2018, Blood.

High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma

W. C. Chan, R. Gascoyne, B. Sander, 2014, Oncogene.

Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

J. Dudley, A. Laganà, S. Jagannath, 2019, Clinical Cancer Research.

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma

J. Dudley, B. Barlogie, D. Auclair, 2018, Leukemia.

Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.

S. Jagannath, E. Reddy, S. Parekh, 2016, Cancer research.

Cancer Therapy : Preclinical Akt Inhibitors MK-2206 and Nel fi navir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma

J. Sparano, S. Parekh, M. Fazzari, 2012 .

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

Amit Verma, Adrian Wiestner, Samir Parekh, 2010, Blood.

High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma

W. Wilson, A. Verma, A. Wiestner, 2011 .

A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma

A. Laganà, S. Jagannath, W. Pierceall, 2020, Leukemia & lymphoma.

SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma

A. Laganà, R. Jain, A. Wiestner, 2021, Clinical Cancer Research.

A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma

A. Laganà, S. Jagannath, D. Madduri, 2022, medRxiv.

A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

A. Laganà, S. Jagannath, Manishkumar Patel, 2015 .

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

A. Laganà, S. Jagannath, S. Parekh, 2017, Blood advances.

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2022, Journal of Hematology & Oncology.

Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2023, Journal of Hematology & Oncology.

Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

A. Laganà, J. Teruya-Feldstein, S. Parekh, 2020 .

Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma

J. Sparano, S. Parekh, M. Fazzari, 2012, Clinical Cancer Research.

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

J. Dudley, B. Barlogie, D. Auclair, 2018, Blood.

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

V. Seshan, B. Tycko, G. Bhagat, 2011, Blood.